AARTIDRUGS

Aarti Drugs Share Price

₹473.80 +4.85 (1.03%)

21 May, 2025 19:39

SIP TrendupStart SIP in AARTIDRUGS

Start SIP

Performance

  • Low
  • ₹467
  • High
  • ₹497
  • 52 Week Low
  • ₹312
  • 52 Week High
  • ₹635
  • Open Price₹467
  • Previous Close₹469
  • Volume408,757

Investment Returns

  • Over 1 Month + 32.55%
  • Over 3 Month + 22.21%
  • Over 6 Month + 3.03%
  • Over 1 Year -2.87%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarti Drugs for Steady Growth!

Invest Now

Aarti Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.7
  • PEG Ratio
  • -13.5
  • Market Cap Cr
  • 4,324
  • P/B Ratio
  • 3.4
  • Average True Range
  • 21.98
  • EPS
  • 18.29
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 23.96
  • RSI
  • 74.26
  • MFI
  • 91.88

Aarti Drugs Financials

Aarti Drugs Technicals

EMA & SMA

Current Price
₹473.80
+ 4.85 (1.03%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹420.80
  • 50 Day
  • ₹393.74
  • 100 Day
  • ₹400.77
  • 200 Day
  • ₹427.88

Resistance and Support

479.15 Pivot Speed
  • R3 522.00
  • R2 509.50
  • R1 491.65
  • S1 461.30
  • S2 448.80
  • S3 430.95

What's your outlook on Aarti Drugs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarti Drugs Ltd. is a leading Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), formulations, and intermediates. It operates in therapeutic segments like antibiotics, anti-diabetics, and cardiovascular, serving global markets with over 50% of revenue from exports.

Aarti Drugs has an operating revenue of Rs. 2,387.03 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 9% is okay, ROE of 12% is good. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 31% and 7% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 48 which is a POOR score indicating inconsistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarti Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-06 Audited Results
2025-01-29 Quarterly Results & Interim Dividend
2024-10-24 Quarterly Results
2024-08-26 Buy Back of Shares
2024-07-26 Quarterly Results
Date Purpose Remarks
2025-02-04 INTERIM Rs.1.00 per share(10%)Interim Dividend
2024-02-06 INTERIM Rs.1.00 per share(10%)Interim Dividend
2023-02-08 INTERIM Rs.1.00 per share(10%)Interim Dividend
2022-02-10 INTERIM Rs.1.00 per share(10%)Interim Dividend
View More

Aarti Drugs F&O

Aarti Drugs Shareholding Pattern

55.48%
8.75%
0.08%
2.25%
0%
23.51%
9.93%

About Aarti Drugs

  • NSE Symbol
  • AARTIDRUGS
  • BSE Symbol
  • 524348
  • Managing Director
  • Mr. Rashesh C Gogri
  • ISIN
  • INE767A01016

Similar Stocks to Aarti Drugs

Aarti Drugs FAQs

Aarti Drugs share price is ₹473 As on 21 May, 2025 | 19:25

The Market Cap of Aarti Drugs is ₹4324.4 Cr As on 21 May, 2025 | 19:25

The P/E ratio of Aarti Drugs is 25.7 As on 21 May, 2025 | 19:25

The PB ratio of Aarti Drugs is 3.4 As on 21 May, 2025 | 19:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23